Biological Cln 2

Brineura

Payments companies reported to CMS as associated with Brineura. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$83Kassociated payments (2023-2025)
378clinicians with associated payments
1company reporting

By year

2023 $43K
2024 $28K
2025 $12K

Payments reported as associated with Brineura, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology With Special Qualifications In Child Neurology $37K
Pulmonary Disease $35K
Pediatrics (Nurse Practitioner) $2,633
Neurology (Psychiatry & Neurology) $2,241
Family $1,054
Pediatrics $796

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Brineura

These are the largest totals companies reported as associated with Brineura. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Ronald Crystal New York, NY Pulmonary Disease $35,000.00
Emily Delosreyes Columbus, OH Neurology With Special Qualifications In Child Neurology $20,481.54
Tracy Glauser Cincinnati, OH Neurology With Special Qualifications In Child Neurology $7,664.00
Jeremy Shefner Phoenix, AZ Neurology (Psychiatry & Neurology) $1,000.00
Jullie Rhee Washington, DC Neonatal, Critical Care $499.18
Yael Shiloh-Malawsky Chapel Hill, NC Neurology With Special Qualifications In Child Neurology $444.60
Andrea Gropman Washington, DC Neurology With Special Qualifications In Child Neurology $265.85
Naterra Weathers Washington, DC Pediatrics (Nurse Practitioner) $230.34
Marie Varnet Colorado Springs, CO Developmental - Behavioral Pediatrics $204.52
Jessica Green Glen Allen, VA Pediatrics (Nurse Practitioner) $203.20

Prescribed Brineura?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.